A BioMedWire editorial published today titled "Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now" highlights the urgent need for new therapies as rare diseases affect more than 30 million Americans. The article features Soligenix Inc. (NASDAQ: SNGX) and its late-stage development of HyBryte(TM) (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (CTCL), which is now in its final confirmatory study before worldwide marketing submissions.
The editorial places Soligenix's efforts at the intersection of advancing treatment options and emerging national health policy initiatives. According to the piece, rare diseases are a growing burden in an aging America, and federal policy must adapt to encourage innovation. The full editorial can be accessed at https://ibn.fm/OFZZt.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company's Specialized BioTherapeutics business segment is developing HyBryte as a novel photodynamic therapy utilizing safe visible light for CTCL. With the successful completion of the second Phase 3 study, regulatory approvals are being sought to support potential commercialization worldwide. Development programs also include expansion of synthetic hypericin (SGX302) into psoriasis, and dusquetide (SGX942) for inflammatory diseases such as oral mucositis in head and neck cancer, and (SGX945) in Behcet's Disease.
The editorial underscores that HyBryte's progress represents a significant step toward addressing the needs of patients with rare diseases. For more information on Soligenix, including the latest news and updates, visit the company's newsroom at https://ibn.fm/SNGX.
